Endocrinology prior authorization at Regence
PA workflow, documentation criteria, and peer-to-peer prep — for prescribers and PA staff
Regence endocrinology PA at a glance
Regence reviews endocrinology PA submissions against its medical policy library, with rules drawn primarily from ADA Standards of Care + AACE/ACE Comprehensive Type 2 Diabetes Management Algorithm. Regence-specific context: BCBS licensee operating in Oregon, Washington (Clark/Cowlitz counties), Idaho, and Utah (~3.1M members). Subsidiary of Cambia Health Solutions. Prime Therapeutics PBM. Each state's DOI handles complaints for policies issued in that state.
Documentation packet — what to send
- Diagnosis (T2D vs obesity vs cardio-renal indication) with ICD-10
- BMI + comorbidities
- Most recent A1c
- Prior diabetes therapies with duration and reason for change
- Cardiovascular or renal comorbidity supporting the cardio-renal indication
Common denial patterns to pre-empt
Patterns observed in endocrinology across payers, and where Regence's book of business overlaps:
- Weight-loss exclusion (Wegovy, Zepbound) — coverage limited to diabetes indication
- Step therapy requiring metformin / SU first
- A1c threshold for GLP-1 initiation not met
- BMI threshold above FDA label for anti-obesity indication
- Quantity limit (28 days vs 90-day supply)
- Step therapy via Prime Therapeutics
Appeal angles when Regence denies
- ADA Standards of Care year-specific recommendation
- Established CV disease (qualifies for cardio-renal indication)
- Established CKD (SGLT-2i / GLP-1 cardio-renal benefit)
- Functional comorbidity (sleep apnea, OA) supporting AOM coverage
Peer-to-peer prep
- Differentiate diabetes-indication semaglutide (Ozempic) from weight-loss (Wegovy) — common P2P confusion point
- Have the latest A1c, lipid panel, eGFR, and UACR open
- Reference the cardiovascular outcome trial by name (SUSTAIN-6, EMPA-REG, SELECT) when arguing for the cardio-renal indication
- Quote the ADA Standards of Care recommendation grade (A, B, C, E)
Drug-specific PA criteria at Regence
Deep dives on each drug's PA criteria at Regence:
Frequently asked questions
What documentation does Regence need for endocrinology prior authorizations?
Regence's PA packet for endocrinology typically includes: Diagnosis (T2D vs obesity vs cardio-renal indication) with ICD-10; BMI + comorbidities; Most recent A1c; Prior diabetes therapies with duration and reason for change. ADA Standards of Care + AACE/ACE Comprehensive Type 2 Diabetes Management Algorithm citations strengthen the submission.
What's the turnaround at Regence?
Regence standard decision: 30 days. Expedited (urgent care): 72 hours per 45 CFR §147.136. Internal appeal window if denied: 180 days.
Which endocrinology drugs does Regence most often PA-restrict?
Top targets in endocrinology: semaglutide, tirzepatide, liraglutide, empagliflozin, dapagliflozin. Each follows the per-drug step therapy + documentation requirements published in Regence's medical policy library.
How do I prep a peer-to-peer with Regence in endocrinology?
Differentiate diabetes-indication semaglutide (Ozempic) from weight-loss (Wegovy) — common P2P confusion point Have the latest A1c, lipid panel, eGFR, and UACR open Have the policy URL and the patient's chart open before the call.
Generate a Endocrinology PA packet
Open ApprovalHelp — generate a endocrinology PA packet tailored to Regence's criteria, with prescriber attestation and supporting citations pre-filled.
Get started →Contact: hello@approvalhelp.com